Published in Alzheimers Dement on July 01, 2011
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage (2012) 1.66
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
In vivo analysis of hippocampal subfield atrophy in mild cognitive impairment via semi-automatic segmentation of T2-weighted MRI. J Alzheimers Dis (2012) 1.30
The diagnosis and management of mild cognitive impairment: a clinical review. JAMA (2014) 1.18
Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage (2012) 1.17
The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement (2014) 1.16
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement (2014) 1.14
Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci (2012) 1.10
Histology-derived volumetric annotation of the human hippocampal subfields in postmortem MRI. Neuroimage (2013) 1.10
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimers Dement (2014) 0.98
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer's disease. Neuroimage Clin (2014) 0.93
An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment. J Intern Med (2013) 0.90
A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. Biol Psychiatry (2013) 0.86
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. JAMA Neurol (2016) 0.84
Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging. J Alzheimers Dis (2015) 0.82
A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease. Neuroimage (2012) 0.82
Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging (2013) 0.81
Science to practice: translating automated brain MRI volumetry in Alzheimer's disease from research to routine diagnostic use in the work-up of dementia. Front Neurol (2014) 0.81
Hippocampal surface deformation accuracy in T1-weighted volumetric MRI sequences in subjects with epilepsy. J Neuroimaging (2014) 0.80
Genomic structural variants are linked with intellectual disability. J Neural Transm (Vienna) (2015) 0.79
Accurate and Fully Automatic Hippocampus Segmentation Using Subject-Specific 3D Optimal Local Maps Into a Hybrid Active Contour Model. IEEE J Transl Eng Health Med (2014) 0.79
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med (2012) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
An expanded role for neuroimaging in the evaluation of memory impairment. AJNR Am J Neuroradiol (2013) 0.78
Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients. BMC Geriatr (2015) 0.77
Segmentation of human brain using structural MRI. MAGMA (2016) 0.77
Automated identification of dementia using medical imaging: a survey from a pattern classification perspective. Brain Inform (2015) 0.76
How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis? Eur Neuropsychopharmacol (2014) 0.76
Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). Trials (2014) 0.76
Emerging biomarkers in cognition. Clin Geriatr Med (2013) 0.76
Early developmental gene enhancers affect subcortical volumes in the adult human brain. Hum Brain Mapp (2016) 0.76
Identify the Atrophy of Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging Using Morphometric MRI Analysis. Front Aging Neurosci (2016) 0.75
Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry. Neuroimage Clin (2016) 0.75
Robust measurement of individual localized changes to the aging hippocampus. Comput Vis Image Underst (2013) 0.75
Manual-Protocol Inspired Technique for Improving Automated MR Image Segmentation during Label Fusion. Front Neurosci (2016) 0.75
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Funct Neurol (2017) 0.75
Multi-Source Learning for Joint Analysis of Incomplete Multi-Modality Neuroimaging Data. KDD (2012) 0.75
The anteroposterior and primary-to-posterior limbic ratios as MRI-derived volumetric markers of Alzheimer's disease. J Neurol Sci (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage (1999) 40.38
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron (2002) 33.99
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain (1996) 4.61
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 4.54
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care (2005) 3.38
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res (2009) 3.31
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. Neurobiol Aging (2006) 3.26
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol (2006) 3.11
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract (2004) 2.99
Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 2.92
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology (2002) 2.87
Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology (2003) 2.85
Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage (2003) 2.77
Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol (2008) 2.71
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain (2009) 2.61
Temporal lobe seizures: lateralization with MR volume measurements of the hippocampal formation. Radiology (1990) 2.56
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol (1993) 2.44
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging (2008) 2.25
EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol (2010) 2.21
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Classification of structural images via high-dimensional image warping, robust feature extraction, and SVM. Med Image Comput Comput Assist Interv (2005) 2.05
Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol (2005) 2.05
Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage (2010) 1.99
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord (2004) 1.91
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease. Neuroimage (2007) 1.83
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology (2004) 1.64
Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology (2008) 1.64
Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. Neuroimage (2009) 1.63
A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging (2008) 1.61
MR-based in vivo hippocampal volumetrics: 1. Review of methodologies currently employed. Mol Psychiatry (2005) 1.60
MRI-based automated computer classification of probable AD versus normal controls. IEEE Trans Med Imaging (2008) 1.58
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol (2007) 1.57
Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.50
Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage (2010) 1.46
Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage (2011) 1.44
A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neuroimage (2008) 1.40
Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement (2011) 1.34
Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.33
Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.33
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology (2009) 1.30
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry. Neuropsychologia (2008) 1.25
Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging (2010) 1.21
Algorithms, atrophy and Alzheimer's disease: cautionary tales for clinical trials. Neuroimage (2011) 1.21
Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J Neurol (2006) 1.16
Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. Neuroimage (2006) 1.01
The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. J Alzheimers Dis (2010) 1.00
Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res (2010) 0.95
Surface-based vector analysis using heat equation interpolation: a new approach to quantify local hippocampal volume changes. Med Image Comput Comput Assist Interv (2008) 0.92
Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Res (2011) 0.90
Hippocampal atrophy rates in Alzheimer's disease: automated segmentation variability analysis. Neurosci Lett (2011) 0.79
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A (2009) 9.19
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis (2003) 8.29
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage (2007) 5.86
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol (2005) 5.55
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Mapping brain asymmetry. Nat Rev Neurosci (2003) 4.99
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
Therapeutic hypothermia after out-of-hospital cardiac arrest in children. N Engl J Med (2015) 4.90
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol (2006) 4.19
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A (2002) 4.07
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain (2010) 3.84
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Dynamics of the hippocampus during encoding and retrieval of face-name pairs. Science (2003) 3.67
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Mapping brain maturation. Trends Neurosci (2006) 3.60
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA (2010) 3.58
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol (2003) 3.44
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol (2003) 3.26
Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb Cortex (2006) 3.23
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed (2009) 3.18
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol (2006) 3.11
Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med (2007) 3.11
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol (2005) 3.10
Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage (2002) 3.06
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05